Literature DB >> 11788366

Increased muscle fatigability in GLUT-4-deficient mice.

M Gorselink1, M R Drost, K F J de Brouwer, G Schaart, G P J van Kranenburg, T H M Roemen, M van Bilsen, M J Charron, G J van der Vusse.   

Abstract

GLUT-4 plays a predominant role in glucose uptake during muscle contraction. In the present study, we have investigated in mice whether disruption of the GLUT-4 gene affects isometric and shortening contractile performance of the dorsal flexor muscle complex in situ. Moreover, we have explored the hypothesis that lack of GLUT-4 enhances muscle fatigability. Isometric performance normalized to muscle mass during a single tetanic contraction did not differ between wild-type (WT) and GLUT-4-deficient [GLUT-4(-/-)] mice. Shortening contractions, however, revealed a significant 1.4-fold decrease in peak power per unit mass, most likely caused by the fiber-type transition from fast-glycolytic fibers (IIB) to fast-oxidative fibers (IIA) in GLUT-4(-/-) dorsal flexors. In addition, the resting glycogen content was significantly lower (34%) in the dorsal flexor complex of GLUT-4(-/-) mice than in WT mice. Moreover, the muscle complex of GLUT-4(-/-) mice showed enhanced susceptibility to fatigue, which may be related to the decline in the muscle carbohydrate store. The significant decrease in relative work output during the steady-state phase of the fatigue protocol suggests that energy supply via alternative routes is not capable to compensate fully for the lack of GLUT-4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788366     DOI: 10.1152/ajpendo.00085.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  8 in total

1.  Glucose kinetics and exercise tolerance in mice lacking the GLUT4 glucose transporter.

Authors:  Patrick T Fueger; Candice Y Li; Julio E Ayala; Jane Shearer; Deanna P Bracy; Maureen J Charron; Jeffrey N Rottman; David H Wasserman
Journal:  J Physiol       Date:  2007-05-10       Impact factor: 5.182

Review 2.  Myosin phosphorylation and force potentiation in skeletal muscle: evidence from animal models.

Authors:  Rene Vandenboom; William Gittings; Ian C Smith; Robert W Grange; James T Stull
Journal:  J Muscle Res Cell Motil       Date:  2013-10-27       Impact factor: 2.698

Review 3.  Rodent models for metabolic syndrome research.

Authors:  Sunil K Panchal; Lindsay Brown
Journal:  J Biomed Biotechnol       Date:  2010-12-30

4.  Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS.

Authors:  Audrey E Brown; Beth Dibnah; Emily Fisher; Julia L Newton; Mark Walker
Journal:  Biosci Rep       Date:  2018-05-08       Impact factor: 3.840

5.  Involvement of IL-1 in the Maintenance of Masseter Muscle Activity and Glucose Homeostasis.

Authors:  Ko Chiba; Masahiro Tsuchiya; Masashi Koide; Yoshihiro Hagiwara; Keiichi Sasaki; Yoshinori Hattori; Makoto Watanabe; Shunji Sugawara; Makoto Kanzaki; Yasuo Endo
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

6.  Exercise-induced muscle glucose uptake in mice with graded, muscle-specific GLUT-4 deletion.

Authors:  Kirsten F Howlett; Sofianos Andrikopoulos; Joseph Proietto; Mark Hargreaves
Journal:  Physiol Rep       Date:  2013-08-22

7.  Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells.

Authors:  Arlek M González-Jamett; Ximena Baez-Matus; María José Olivares; Fernando Hinostroza; Maria José Guerra-Fernández; Jacqueline Vasquez-Navarrete; Mai Thao Bui; Pascale Guicheney; Norma Beatriz Romero; Jorge A Bevilacqua; Marc Bitoun; Pablo Caviedes; Ana M Cárdenas
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

8.  Estrogen weakens muscle endurance via estrogen receptor-p38 MAPK-mediated orosomucoid (ORM) suppression.

Authors:  Yang Sun; Zhen Qin; Jing-Jing Wan; Peng-Yuan Wang; Yi-Li Yang; Jian-Guang Yu; Bo-Han Hu; Ding-Feng Su; Zhu-Min Luo; Xia Liu
Journal:  Exp Mol Med       Date:  2018-03-30       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.